ArticleAmerican journal of cancer research2025
Effects of
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer medicine · 2026Review
- Clinical characteristics and risk analysis of lymph node metastasis in patients with cN0 differentiated thyroid carcinoma.Scientific reports · 2026Article
- Multidisciplinary treatment of follicular thyroid carcinoma with hepatic and pulmonary metastases: a case report and literature review.Frontiers in medicine · 2026Article
- Mechanism of METTL14-mediated RAD21 mRNA epigenetic transcriptome modification in inhibiting thyroid cancer development.World journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the changes in the expression levels of METTL3 and METTL14 in patients with differentiated thyroid cancer (DTC) and their association with thyroid function indicators, as well as to explore the potential value of these genes in predicting the risk of DTC recurrence.
methodsThis cohort study included 189 DTC patients treated at Shidong Hospital between April 2016 and February 2021. Patients were divided into an experimental group, which received combined radioactive iodine (
resultsBoth METTL3 and METTL14 expression levels significantly decreased after treatment in both the experimental and control groups (P < 0.001). Regarding thyroid function indicators, FT3 and FT4 levels significantly increased, while TSH and Tg levels significantly decreased post-treatment (P < 0.001). Lower post-treatment expression levels of METTL3 and METTL14 were significantly associated with a higher risk of recurrence. Cox regression analysis further indicated that post-treatment METTL3, METTL14, TSH, and Tg levels were independent predictors of DFS (P < 0.05).
conclusionLow expression levels of METTL3 and METTL14 are closely associated with malignant progression and an increased risk of recurrence in DTC. Patients receiving combined
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.